DCGI nod to Bajaj Healthcare for manufacturing Parkinson's disease psychosis drug Pimavanserin in India Ruchika Sharma31 Jan 2025 11:30 AM ISTMumbai: Bajaj Healthcare Limited has announced that it has received approval from the Drug Controller General of India (DCGI) to manufacture both...
Sun Pharma's proposal to amend CT protocol for pimavanserin gets CDSCO Panel nod Dr. Divya Colin2 Jan 2023 6:00 PM ISTNew Delhi: Approving Sun Pharma's proposal to amend the existing clinical trial protocol for the atypical antipsychotic Pimavanserin Capsules, the...
Pimavanserin administration does not notably impact severity of obstructive sleep apnea Medha Baranwal11 Oct 2022 10:00 AM ISTUSA: A single pimavanserin dose does not significantly impact arousal threshold or obstructive sleep apnea (OSA) severity, a recent study published in...
Pimavanserin increases mortality in elderly with Parkinson's disease: Study MD Editorial Team7 Sept 2021 9:00 AM ISTAccording to a new study published in the Journal Neurology, older persons with Parkinson's disease (PD) who used pimavanserin had an increased risk...
Pimavanserin reduces symptoms of dementia-related psychosis in phase 3 trial Hina Zahid31 July 2020 7:06 AM ISTA large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms...
Parkinson's drug Pimavanserin may help treat NAFLD, finds study Dr. Kamal Kant Kohli29 May 2020 7:07 PM ISTNonalcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat accumulation in the liver that can lead to serious...
